Quantcast

Latest CBLB502 Stories

2010-04-25 09:00:00

BUFFALO, N.Y., April 25 /PRNewswire-FirstCall/ -- Cleveland BioLabs (CBLI) announces the following Webcast: What: Cleveland Biolabs Investor Update Call When: April 28, 2010 @ 10:00 AM Eastern Where: http://www.investorcalendar.com/ClientPage.asp?ID=157342 Live over the Internet --Simply log on to the web at the address How: above. Contact: Rachel Levine, 646-284-9439, rlevine@cbiolabs.com If you are unable to participate during the...

2008-11-03 09:00:40

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York City, November 10-12, 2008. The conference will be held at The New York Palace Hotel. Management will be available to meet with investors or licensing partners November 10-11. Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a presentation on the Company's lead compounds and development...

2008-10-30 15:00:38

A U.S. company says it's started initial human safety testing of a drug designed to treat exposure to radiation from nuclear weapons or a nuclear accident. Cleveland BioLabs Inc. said it dosed its first healthy volunteer this month in the human safety study required by the U.S. Food and Drug Administration for the drug Protectan CBLB502. The safety trial involves single injections of Protectan CBLB502 in ascending dose groups of six healthy volunteers each. Participants in the study will...

2008-10-21 09:00:54

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will present at the 2008 BIO Investor Forum in San Francisco, October 29-31, 2008. The conference will be held at The Palace Hotel in San Francisco. Management will be available to meet with investors or licensing partners October 29-30. Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a presentation on the Company's lead compounds and development strategy on October 30, at...

2008-10-17 12:00:25

Cleveland BioLabs, a drug discovery and development company, has dosed the first healthy volunteer in the initial human safety study for Protectan CBLB502, a drug under development for the treatment of acute radiation syndrome. This initial safety study will involve single injections of Protectan CBLB502 in ascending dose groups of six healthy volunteers each. Participants in the study will be assessed for adverse side effects over a two-week time period and blood samples will be obtained...

2008-10-15 09:00:47

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on October 14, the first healthy volunteer was dosed in the initial human safety study for Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS). Protectan CBLB502 is being developed under the FDA's animal efficacy rule to treat radiation injury following exposure to radiation from nuclear or radiological weapons, or from nuclear accident. This approval pathway requires demonstration of...

2008-09-29 09:00:58

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Maxim Group Growth Conference in New York City on Tuesday, October 7, 2008. The conference will be held at the Grand Hyatt New York Hotel. The Maxim Group Growth Conference will feature interactive presentations from over 80 companies, as well as one-on-one meetings with executives from the Healthcare, Technology, Shipping/Transportation and Emerging Growth Sectors. Attendees will...

2008-09-23 09:01:09

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that it will present Protectan CBLB502 at the 2008 Biomedical Advanced Research and Development Authority (BARDA) Stakeholders Workshop and Industry Day, September 24-26, in Washington, DC. Cleveland BioLabs Chief Scientific Officer, Andrei Gudkov, Ph.D., D. Sci., has been invited to speak on Wednesday, September 24, at the Radiological and Nuclear Therapeutics Session. His presentation, titled "Protectan CBLB502 Prevents and Mitigates...

2008-09-16 12:00:50

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) has awarded the Company a contract under the Broad Agency Announcement titled, "Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation," for selected tasks in the advanced development of Protectan CBLB502. The total contract...

2008-09-15 09:00:58

Cleveland BioLabs, a drug discovery and development company, has received a $774,183 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic damage from radiation exposure. The grant program, medical countermeasures to enhance platelet regeneration and increase survival following radiation exposure, is funded through the Project BioShield Act...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'